Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US

The objective of this study was to describe real-world adjuvant therapy (AT) use by disease substage and assess determinants of treatment choice among patients with stage III melanoma.

Source: BMC Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Eric D. Whitman, Todor I. Totev, Shan Jiang, Wilson L. da Costa Jr., Dmitri Grebennik, Hongjue Wang, Andra-Ecaterina Boca and Rajeev Ayyagari Tags: Research Source Type: research